Shopping Cart
Remove All
Your shopping cart is currently empty
IR415 selectively interacts with Hepatitis B virus X protein (HBx, Kd = 2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease. IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $38 | In Stock | In Stock | |
| 10 mg | $68 | In Stock | In Stock | |
| 25 mg | $137 | In Stock | In Stock | |
| 50 mg | $238 | In Stock | In Stock | |
| 100 mg | $353 | In Stock | In Stock | |
| 200 mg | $493 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $42 | In Stock | In Stock |
| Description | IR415 selectively interacts with Hepatitis B virus X protein (HBx, Kd = 2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease. IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity. |
| Targets&IC50 | HBx:2 nM(Kd) |
| In vitro | IR415, at concentrations ranging from 50 to 200 μM, exhibits a dose-dependent inhibition of the Hepatitis B virus X protein (HBx), achieving its minimal effective concentration at 50 μM in the HepG2/GFP-shRNA line expressing HBx. HBx is identified as a suppressor of the host's defense mechanisms, specifically involved in the RNAi-based silencing of viral genes. |
| Molecular Weight | 296.34 |
| Formula | C13H14F2N4S |
| Cas No. | 452967-14-5 |
| Smiles | Fc1ccc(NC(=S)NCCCn2ccnc2)c(F)c1 |
| Relative Density. | 1.32 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125 mg/mL (421.81 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (13.5 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.